⌘K
Loading ticker…
As of 2026-08-24, Charles River Laboratories International, Inc. (CRL) has a 3-month relative strength percentile of 97 and a leadership percentile of 99 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 76. The current market Stance is 47.8 (Neutral). Sector: Industrials, ranked 6 of 11. Average daily range 3.9%, relative volume 0.80×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CRL is in a stage 2 uptrend, week 7. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 26.3% / 53.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
CRL is held by 44 ETFs as of May 2026. Top owner: VHT at 0.14% weight, $27M notional. Top 3 carry $60M.
Held by 165 ETFs · $1.8B across latest filings · largest weight 1.90% (SAEF).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.14% | $27M | +0.01 pp |
| SCHMSchwab U.S. Mid-Cap ETF | 0.17% | $24M | — |
| SCHXSchwab U.S. Large-Cap ETF | 0.01% | $9M | — |
| SPHBInvesco S&P 500 High Beta ETF | 0.80% | $8M | −0.12 pp |
| VONV |
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.03% |
| $6M |
| — |
| FNDXSchwab Fundamental U.S. Large Company Index ETF | 0.02% | $6M | — |
| SCHBSchwab U.S. Broad Market ETF | 0.01% | $5M | — |
| SCHVSchwab U.S. Large-Cap Value ETF | 0.03% | $4M | — |
| ESML | 0.16% | $4M | — |
| VOOV | 0.03% | $2M | — |
Showing 10 of 44 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRL Jan avg: -0.53% median: -1.50% win: 50% σ: 10.84% n: 4 2022-04-12 → 2026-07-31 | CRL Feb avg: -1.79% median: -4.75% win: 50% σ: 14.40% n: 4 2022-04-12 → 2026-07-31 | CRL Mar avg: -3.42% median: -5.67% win: 25% σ: 7.11% n: 4 2022-04-12 → 2026-07-31 | CRL Apr avg: -12.52% median: -15.48% win: 0% σ: 7.67% n: 5 2022-04-12 → 2026-07-31 | CRL May avg: 2.45% median: 1.71% win: 60% σ: 9.17% n: 5 2022-04-12 → 2026-07-31 | CRL Jun avg: 7.32% median: 8.72% win: 60% σ: 12.98% n: 5 2022-04-12 → 2026-07-31 | CRL Jul avg: 9.85% median: 11.80% win: 80% σ: 8.41% n: 5 2022-04-12 → 2026-07-31 | CRL Aug avg: -10.52% median: -10.90% win: 0% σ: 9.31% n: 4 2022-04-12 → 2026-07-31 (current) | CRL Sep avg: -3.49% median: -4.16% win: 0% σ: 2.12% n: 4 2022-04-12 → 2026-07-31 | CRL Oct avg: -0.12% median: -0.74% win: 50% σ: 13.84% n: 4 2022-04-12 → 2026-07-31 | CRL Nov avg: 8.79% median: 9.58% win: 75% σ: 7.62% n: 4 2022-04-12 → 2026-07-31 | CRL Dec avg: 5.00% median: 3.66% win: 50% σ: 13.12% n: 4 2022-04-12 → 2026-07-31 |